BIO79 VENTURE PARTNERS
DEAD

Serial Number

98149128

Owner

Bio79 Venture Partners, LLC

Attorney

Devon E. White

Filing Date

Aug 24, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BIO79 VENTURE PARTNERS Trademark

Serial Number: 98149128

BIO79 VENTURE PARTNERS is a trademark filed by Bio79 Venture Partners, LLC on August 24, 2023. The trademark is classified under Class 36 (Insurance & Financial), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Bio79 Venture Partners, LLC

1111 Kane Concourse, Suite 301
Bay Harbor Islands, FL 33154

Entity Type: 16

Trademark Details

Filing Date

August 24, 2023

Registration Date

Not Registered

Goods & Services

new business venture development and formation consulting services in the field of innovative pharmaceutical and biotechnology products; business support services, namely, business consulting, business development, business venture and formation consulting, business growth consulting, and business management to startup and emerging companies in the in the field of innovative pharmaceutical and biotechnology products; strategic management and business advisory services in the fields of management, business development, licensing, merger and acquisition, venture capital and financing services in the field of innovative pharmaceutical and biotechnology products

venture capital services, namely, providing financing to startup and emerging companies that are believed to have long-term growth potential in the field of innovative pharmaceutical and biotechnology products; providing venture capital, development capital, private equity and investment funding to startup companies and small businesses in the field of innovative pharmaceutical and biotechnology products; venture capital financing in the field of innovative pharmaceutical and biotechnology products; financial services, namely, investment management of strategic venture funds focused on innovative pharmaceutical and biotechnology products; strategic financial investments in startup and emerging companies that are believed to have long-term growth potential in the field of innovative pharmaceutical and biotechnology products

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Aug 8, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 8, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 24, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 24, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 24, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 25, 2023 NWOS
NEW APPLICATION ENTERED
Aug 28, 2023 NWAP